Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise
CEO Says Danish Biotech Wants To Soon Raise $100-$150m
SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.
You may also be interested in...
A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.
Mikaela Odlander, one of In Vivo’s 2021 Rising Leaders, was appointed director of digital therapeutics at Orexo in November 2019. The newly formed digital therapeutics (DTx) arm of the Swedish pharma and digital health company entered the American health care landscape in 2020 with two new products that address substance abuse and mental health problems.
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.